| Date | Title | Description |
| 20.09.2022 | How 3 companies merged and raised $100M to treat range of diseases by pulsing cells (San Francisco Business Times) | By Ron Leuty
Republished with permission from San Francisco Business Times
Three related companies are coming together as one to develop pulsed electric field therapies — basically using energy to make cells do what doctors want them to d... |
| 15.09.2022 | Galvanize Therapeutics Announces Merger to Create the Premier Pulsed Electric Field Therapy Company and Completion of $100 Million Series B Financing | Merger unites three companies created by life sciences venture capital firm ATP—Gala Therapeutics, Galaxy Medical, and Galvanize Therapeutics—to create a single company based on the AliyaTM Pulsed Electric Field (PEF) energy platform
Galva... |
| 08.02.2022 | Gala Therapeutics Announces First Commercial Cases Worldwide with RheOx® System for Chronic Bronchitis | SAN CARLOS, Calif., Feb. 8, 2022 /PRNewswire/ -- Gala Therapeutics, Inc. (Gala), a developer of medical devices to treat pulmonary disease, today announced the first worldwide commercial procedures using the RheOx® Bronchial Rheoplasty syst... |
| 31.08.2021 | Data from Multiple Studies Show Positive Outcomes with Gala Therapeutics' RheOx™ System for Chronic Bronchitis | SAN CARLOS, Calif., Aug. 31, 2021 /PRNewswire/ -- Gala Therapeutics, Inc. (Gala), a developer of medical devices to treat pulmonary disease, today announced new data from multiple clinical studies that demonstrate improvements in chronic br... |
| 31.08.2021 | Data from Multiple Studies Show Positive Outcomes with Gala Therapeutics' RheOx™ System for Chronic Bronchitis | |
| 20.05.2021 | Gala Therapeutics Announces First Patients Enrolled in Pivotal Trial of RheOx™ System for Chronic Bronchitis | |
| 20.05.2021 | Gala Therapeutics Announces First Patients Enrolled in Pivotal Trial of RheOx™ System for Chronic Bronchitis | SAN CARLOS, Calif., May 20, 2021 /PRNewswire/ -- Gala Therapeutics, Inc. (Gala), a developer of medical devices to treat pulmonary disease, has initiated its pivotal clinical trial to evaluate its RheOx™ Bronchial Rheoplasty System for the ... |
| 02.03.2021 | Doug Godshall to Chair Gala Therapeutics Board of Directors | SAN CARLOS, Calif., March 2, 2021 /PRNewswire/ -- Gala Therapeutics, Inc. (Gala), a developer of medical devices to treat chronic bronchitis and other pulmonary diseases, announced today that it has appointed Douglas Godshall to chair its B... |
| 22.02.2021 | Gala Therapeutics Receives FDA Approval to Commence Pivotal Trial to Evaluate the RheOx™ System for Chronic Bronchitis | SAN CARLOS, Calif., Feb. 22, 2021 /PRNewswire/ -- Gala Therapeutics, Inc. (Gala), a developer of medical devices to treat pulmonary disease, announces U.S. Food and Drug Administration (FDA) conditional Investigational Device Exemption (IDE... |
| 22.02.2021 | Gala Therapeutics Receives FDA Approval to Commence Pivotal Trial to Evaluate the RheOx™ System for Chronic Bronchitis | SAN CARLOS, Calif., Feb. 22, 2021 /PRNewswire/ -- Gala Therapeutics, Inc. (Gala), a developer of medical devices to treat pulmonary disease, announces U.S. Food and Drug Administration (FDA) conditional Investigational Device Exemption (IDE... |
| 22.02.2021 | Gala Therapeutics Receives FDA Approval to Commence Pivotal Trial to Evaluate the RheOx™ System for Chronic Bronchitis | |
| 09.09.2020 | Gala Therapeutics’ RheOx™ System Showcased at Virtual European Respiratory Society Congress | Menlo Park, CA, Sept. 9, 2020 – Gala Therapeutics, Inc. (Gala), a developer of medical devices to treat pulmonary disease, today announced that a live case featuring its RheOx™ Bronchial Rheoplasty System was performed during the virtual Eu... |
| 09.09.2020 | Gala Therapeutics’ RheOx™ System Showcased at Virtual European Respiratory Society Congress | Menlo Park, CA, Sept. 9, 2020 – Gala Therapeutics, Inc. (Gala), a developer of medical devices to treat pulmonary disease, today announced that a live case featuring its RheOx™ Bronchial Rheoplasty System was performed during the virtual Eu... |
| 03.09.2020 | Results Published from Multicenter Study of Gala Therapeutics' Minimally Invasive RheOx™ System in Patients with Chronic Bronchitis | MENLO PARK, Calif., Sept. 3, 2020 /PRNewswire/ -- Gala Therapeutics, Inc. (Gala), a developer of medical devices to treat pulmonary disease, today announced the publication of the results from its initial study evaluating the RheOx (TM) Bro... |
| 03.09.2020 | Results Published from Multicenter Study of Gala Therapeutics' Minimally Invasive RheOx™ System in Patients with Chronic Bronchitis | MENLO PARK, Calif., Sept. 3, 2020 /PRNewswire/ -- Gala Therapeutics, Inc. (Gala), a developer of medical devices to treat pulmonary disease, today announced the publication of the results from its initial study evaluating the RheOx (TM) Bro... |
| 03.09.2020 | Gala Therapeutics Announces Publication of Multicenter Study of the Minimally Invasive RheOx™ System in Patients with Chronic Bronchitis | |
| 16.09.2019 | Gala Therapeutics Receives FDA Breakthrough Device Designation for the Minimally Invasive RheOx™ System for Chronic Bronchitis | MENLO PARK, Calif., Sept. 16, 2019 --(PRNewswire)-- Gala Therapeutics, Inc. (Gala), a developer of medical devices to treat pulmonary disease, announced the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation (FD... |
| 16.09.2019 | Gala Therapeutics Receives FDA Breakthrough Device Designation for the Minimally Invasive RheOx™ System for Chronic Bronchitis | MENLO PARK, Calif., Sept. 16, 2019 --(PRNewswire)-- Gala Therapeutics, Inc. (Gala), a developer of medical devices to treat pulmonary disease, announced the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation (FD... |
| 04.09.2019 | Gala Therapeutics Receives CE Mark for its Minimally Invasive RheOx™ System for Chronic Bronchitis | MENLO PARK, Calif., Sept. 4, 2019 -- (PRNewswire) -- Gala Therapeutics, Inc. (Gala), today announced that its RheOx™ system has received CE Mark in the European Union. In a minimally invasive procedure called Bronchial Rheoplasty™, RheOx de... |
| 04.09.2019 | Gala Therapeutics Receives CE Mark for its Minimally Invasive RheOx™ System for Chronic Bronchitis | MENLO PARK, Calif., Sept. 4, 2019 -- (PRNewswire) -- Gala Therapeutics, Inc. (Gala), today announced that its RheOx™ system has received CE Mark in the European Union. In a minimally invasive procedure called Bronchial Rheoplasty™, RheOx de... |
| 23.05.2019 | Initial Study of Gala's Minimally Invasive RheOx™ Device Demonstrates Positive Results for Chronic Bronchitis Patients | DALLAS, May 23, 2019 -- (PRNewswire) -- Gala Therapeutics, Inc. (Gala), a clinical-stage developer of medical devices to treat pulmonary disease, today announced new results from the initial study of its investigational RheOxTM device, demo... |
| 23.05.2019 | Initial Study of Gala's Minimally Invasive RheOx™ Device Demonstrates Positive Results for Chronic Bronchitis Patients | DALLAS, May 23, 2019 -- (PRNewswire) -- Gala Therapeutics, Inc. (Gala), a clinical-stage developer of medical devices to treat pulmonary disease, today announced new results from the initial study of its investigational RheOxTM device, demo... |
| 17.01.2019 | Gala Enrolls First Subject at Temple Lung Center as Part of the US Early Feasibility Trial of RheOx™ for Chronic Bronchitis in the United States | Menlo Park, Calif, January 17, 2019 – Gala Therapeutics (Gala), a clinical-stage developer of medical devices to treat pulmonary disease, today announced that the first patient at Temple Lung Center in Philadelphia, Pennsylvania was treated... |
| 17.01.2019 | Gala Enrolls First Subject at Temple Lung Center as Part of the US Early Feasibility Trial of RheOx™ for Chronic Bronchitis in the United States | Menlo Park, Calif, January 17, 2019 – Gala Therapeutics (Gala), a clinical-stage developer of medical devices to treat pulmonary disease, today announced that the first patient at Temple Lung Center in Philadelphia, Pennsylvania was treated... |
| 05.11.2018 | Gala Enrolls First Subjects in an Early Feasibility Study of RheOx™ for Chronic Bronchitis in the United States | Menlo Park, Calif, November 5, 2018 – Gala Therapeutics (Gala), a clinical-stage developer of medical devices to treat pulmonary disease, today announced that the first two patients in the Early Feasibility Study of RheOx™ for Chronic Bronc... |
| 05.11.2018 | Gala Enrolls First Subjects in an Early Feasibility Study of RheOx™ for Chronic Bronchitis in the United States | Menlo Park, Calif, November 5, 2018 – Gala Therapeutics (Gala), a clinical-stage developer of medical devices to treat pulmonary disease, today announced that the first two patients in the Early Feasibility Study of RheOx™ for Chronic Bronc... |
| 17.09.2018 | Gala Presents Positive Results from First-In-Human Clinical Trial of RheOx™ in Chronic Bronchitis at the European Respiratory Society | - Favorable safety profile
- RheOx treatment resulted in clinical improvement as measured by Quality of Life scores, with treatment effect maintained at 12-month follow-up
- Improvement in airway biopsies and imaging
MENLO PARK, Calif., ... |
| 17.09.2018 | Gala Presents Positive Results from First-In-Human Clinical Trial of RheOx™ in Chronic Bronchitis at the European Respiratory Society | - Favorable safety profile |
| 08.08.2018 | Data From First-In-Human RheOx™ Bronchial Rheoplasty Trial to be Presented at the European Respiratory Society | Menlo Park, Calif, August 8, 2018 – Gala Therapeutics (Gala), a clinical-stage developer of medical devices to treat pulmonary disease, today announced that data from a Late-Breaking Abstract from a first-in-human study of the Rheox™ system... |
| 08.08.2018 | Data From First-In-Human RheOx™ Bronchial Rheoplasty Trial to be Presented at the European Respiratory Society | Menlo Park, Calif, August 8, 2018 – Gala Therapeutics (Gala), a clinical-stage developer of medical devices to treat pulmonary disease, today announced that data from a Late-Breaking Abstract from a first-in-human study of the Rheox™ system... |
